- Sunitinib has been approved for treatment of gastrointestinal stromal tumors.
- In a clinical trial, Olanzapine was shown to control chemotherapy-induced nausea and vomiting.
- The NCI is aiming its anti-smoking text message program at teen smokers.
- A new class of cancer drugs use antibodies to deliver targeted chemotherapy, reducing side effects.
MSKCC in the News: May 22 – June 6
- MSKCC’s James Allison is quoted in a Bloomberg News article about findings that show therapies like the Bristol drug, that prompt killer T-cells to eliminate invaders, may work against many tumors.
- In a New York Times article, Chaya S. Moskowitz, a biostatistician at MSKCC, indicates that the breast cancer risk for those treated with high radiation doses for Hodgkin’s lymphoma is similar to that for women with mutations in the BRCA1 gene.
- Dr. Clifford A. Hudis of MSKCC is quoted in a New York Times article about a study that shows a drug, known as T-DM1, that delivers a powerful poison to tumors without some of the side effects of traditional treatments can delay the worsening of breast cancer and also appears to substantially prolong lives.
Blog Buzz: May 28 – June 1
This week on the web, a young patient’s update on life with cancer, open access news, Windows 8, and more…
Suleika Jaouad writes a poignant new update for her “Life, Interrupted” column about living with cancer on NY Times’ Well blog.
UCSF has announced an open access policy!
There is an excellent post on the BioMed Central Blog about the Open Access Petition on the We the People website.
The Windows 8 Release Preview is out…and there is lots of coverage. Here is some from the Washington Post.
Hack (Higher) Education reports that etextbook publisher Inkling has a new HTML5 app making their books available on the web.